EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Clinical Characteristics and Safety Profiles of Japanese Psoriasis Patients Who Continued Apremilast Treatment for 6 and 12 Months: A Post Hoc Analysis of an Apremilast Postmarketing Surveillance Study

Mamitaro Ohtsuki iD, Yukari Okubo iD, Hidehisa Saeki iD, Atsuyuki Igarashi, Shinichi Imafuku iD, Masatoshi Abe iD, Katsuya Saito, Ryuichi Ogawa, Akimichi Morita iD

The Journal of Dermatology · 2025

DOI: 10.1111/1346-8138.17764 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Mamitaro Ohtsuki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Jichi Medical University, Shimotsuke, Japan. Hauptthemen laut MEDLINE: Psoriasis, Thalidomide, Phosphodiesterase 4 Inhibitors, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amgen K.K..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Apremilast is a phosphodiesterase 4 inhibitor approved for moderate to severe psoriasis in Japan. Apremilast significantly improved Physician's Global Assessment (PGA) and Dermatology Life Quality Index (DLQI) both at 6 and 12 months in a previously published primary post‐surveillance study. Here, we performed a post hoc analysis of the surveillance data to evaluate patient characteristics, effectiveness, and safety among psoriasis patients who continued apremilast for 6 and 12 months. The PMS included 992 patients, of whom 646 of 992 patients continued treatment for 6 months and 509 of 992 patients subsequently continued treatment for 12 months. Baseline characteristics between these groups were similar. Among 992 patients, the treatment persistence rate was 65.1% at 6 months and 51.3% at 12 months after the start of apremilast treatment. PGA 0/1 response was 47.9% at 6 months and 60.8% at 12 months, whereas DLQI 0/1 responses at 6 months and 12 months were 38.5% and 58.7%, respectively. Among 646 patients who continued apremilast for 6 months, diarrhea was reported in 60 patients (9.3%), nausea in 35 patients (5.4%), and headache in 11 (1.7%) patients, which were mainly observed within the first month since treatment initiation. In 509 patients who continued apremilast for 12 months, diarrhea was reported in 43 patients (8.5%), nausea in 24 patients (4.7%), and headache in 6 (1.2%) patients; similar frequencies of these adverse reactions were observed within 6 months and between 6 and 12 months of follow‐up. It is important to continue apremilast by appropriately managing diarrhea and nausea in real‐world practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisThalidomidePhosphodiesterase 4 InhibitorsAnti-Inflammatory Agents, Non-SteroidalHumansMaleFemaleProduct Surveillance, PostmarketingMiddle AgedJapanAdultTreatment OutcomeAgedSeverity of Illness IndexQuality of LifeDiarrheaTime FactorsEast Asian People

Stichwörter der Autor:innen

Japanapremilastpostmarketing product surveillancepsoriasissafety

Substanzen

apremilastThalidomidePhosphodiesterase 4 InhibitorsAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • Department of Dermatology, Jichi Medical University, Shimotsuke, Japan.
  • Department of Dermatology, Tokyo Medical University, Tokyo, Japan.
  • Department of Dermatology, Nippon Medical School, Tokyo, Japan.
  • Igarashi Dermatology Higashi-Gotanda Clinic, Tokyo, Japan.
  • Department of Dermatology, Fukuoka University, Fukuoka, Japan.
  • Kojinkai Sapporo Skin Clinic, Sapporo, Japan.

ORCID-Profile: Mamitaro Ohtsuki, Yukari Okubo, Hidehisa Saeki, Shinichi Imafuku, Masatoshi Abe, Akimichi Morita

Förderung

  • Amgen K.K.

Zitieren

APA

Ohtsuki, M., Okubo, Y., Saeki, H., Igarashi, A., Imafuku, S., Abe, M., Saito, K., Ogawa, R., & Morita, A. (2025). Clinical Characteristics and Safety Profiles of Japanese Psoriasis Patients Who Continued Apremilast Treatment for 6 and 12 Months: A Post Hoc Analysis of an Apremilast Postmarketing Surveillance Study. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17764

Vancouver

Ohtsuki M, Okubo Y, Saeki H, Igarashi A, Imafuku S, Abe M, et al. Clinical Characteristics and Safety Profiles of Japanese Psoriasis Patients Who Continued Apremilast Treatment for 6 and 12 Months: A Post Hoc Analysis of an Apremilast Postmarketing Surveillance Study. The Journal of Dermatology. 2025. doi:10.1111/1346-8138.17764

BibTeX
@article{Ohtsuki2025,
  author = {Ohtsuki, Mamitaro and Okubo, Yukari and Saeki, Hidehisa and Igarashi, Atsuyuki and Imafuku, Shinichi and Abe, Masatoshi and Saito, Katsuya and Ogawa, Ryuichi and Morita, Akimichi},
  title = {Clinical Characteristics and Safety Profiles of Japanese Psoriasis Patients Who Continued Apremilast Treatment for 6 and 12 Months: A Post Hoc Analysis of an Apremilast Postmarketing Surveillance Study},
  journal = {The Journal of Dermatology},
  year = {2025},
  doi = {10.1111/1346-8138.17764}
}
Kostenlos starten →